AbbVie to present new Mavyret data at AASLD 2017

AbbVie has announced that it will be presenting new clinical trial data on its hepatitis C therapy Mavyret at this year's Liver Meeting.

The company will attend the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC from October 20th to 24th, and will present a total of 16 scientific abstracts.

During the conference, clinical study results on the once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus will be shared, showing Mavyret's effectiveness across all major genotypes.

This includes two oral presentations studying the use of Mavyret in patients across genotypes 1 to 6 with compensated cirrhosis, and treatment-naive patients with genotype 3 hepatitis C, all of whom have historically had limited treatment options.

Meanwhile, a third oral presentation will evaluate adherence to treatment with this drug during the clinical development programme.

Dr Janet Hammond, vice-president for infectious disease development at AbbVie, said: "This data adds to a robust collection of clinical trial results to further enhance scientific knowledge of Mavyret's safety and efficacy across a number of patient populations."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.